Table 5 |
|||||||||
|
Frequencies of CBC patients carrying apathogenic DNA-damage repair pathway mutation |
|||||||||
| Interval (years) |
All CBC patients |
Previous RT |
No RT |
Carriers versus non-carriers |
|||||
| n |
Percentage |
n |
Percentage |
n |
Percentage |
OR for CBC after RT |
95% CI |
p |
|
|
|
|||||||||
| 1–5 (n = 66) |
15/66 |
22.7 |
12/49 |
24.5 |
3/16 |
18.8 |
1.41 |
0.34–5.78 |
|
| >5 (n = 181) |
36/181 |
19.9 |
29/120 |
24.1 |
7/62 |
11.3 |
2.51 |
1.03–6.10 |
0.049 |
|
|
|||||||||
|
All contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure are presented, according to interval between first and second primary breast cancer (less than 5 and more than 5 years). Odds ratio (OR) and 95% confidence interval (CI) are given for mutation carriers versus non-carriers to develop radiation-associated breast cancer. RT, radiation treatment. |
|||||||||
|
Broeks et al. Breast Cancer Research 2007 9:R26 doi:10.1186/bcr1668 |
|||||||||
